Evaluation of gradient strip diffusion for susceptibility testing of aztreonam-avibactam in metallo-β-lactamase-producing Enterobacterales

被引:0
|
作者
Lemon, Jamie K. [1 ,2 ]
Jankowsi-Romano, Cheryl [1 ]
Duong, Scott [1 ,2 ]
Juretschko, Stefan [1 ,2 ]
Streva, Vincent A. [1 ,2 ]
机构
[1] Northwell Hlth Clin Labs, New York, NY 10075 USA
[2] Donald & Barbara Zucker Sch Med Hofstra Northwell, Manhasset, NY 11549 USA
关键词
metallo-beta-lactamase; aztreonam-avibactam; antimicrobial susceptibility testing; NDM; gradient strip diffusion;
D O I
10.1128/jcm.00649-24
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The emergence of metallo-beta-lactamase (MBL)-producing Enterobacterales presents unique clinical treatment challenges. Recently developed beta-lactam/ beta-lactamase inhibitor combination agents, while effective against other carbapenemase-producing organisms, are notably ineffective against MBL producers. While MBLs do not hydrolyze monobactams (aztreonam), many MBL-producing organisms are resistant to aztreonam through alternate mechanisms, leaving cefiderocol as the sole monotherapy treatment option recommended for MBL producers. Recent guidelines for the treatment of MBL-harboring organisms have added combination therapy with aztreonam and ceftazidime-avibactam, using ceftazidime-avibactam as a source of the beta-lactamase inhibitor avibactam. Current laboratory testing options for the combination of aztreonam-avibactam are limited to broth microdilution (BMD) and broth disk elution (BDE) methods, which are not practical in most clinical laboratories. In this study, we evaluated the performance of aztreonam/avibactam gradient strips on 103 MBL-producing Enterobacterales patient isolates as well as an additional 31 isolates from the CDC AR Bank. All MBL Enterobacterales patient isolates included in this study harbored a New Delhi metallo-beta-lactamase (blaNDM) gene. Essential agreement of gradient strip minimal inhibitory concentrations (MICs) for patient isolates compared to BMD was 93.2%. While there are no established breakpoints for aztreonam-avibactam, category agreement (CA) for patient isolates was 97.1% when using the CLSI aztreonam breakpoints. There were no major or very major errors observed. There were three minor errors. Precision for aztreonam-avibactam gradient strip diffusion was 100%. These data demonstrate that the use of gradient strip diffusion for aztreonam-avibactam MIC determination in MBL-producing Enterobacterales is a viable option for clinical laboratories.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Comparison of ETEST® superposition method and the MTS™ Aztreonam-avibactam strip with the reference method for aztreonam/avibactam susceptibility testing
    Deschamps, Manon
    Dauwalder, Ollivier
    Dortet, Laurent
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2024, 79 (03) : 685 - 687
  • [22] A Study on Ceftazidime/Avibactam and Aztreonam Synergy Among Aztreonam-resistant Metallo-(3-lactamase Producing Enterobacterales in a Tertiary Care Hospital
    D'souza, Adelyn
    Shetty, Rachana
    Pai, K. B. Asha
    MEDITERRANEAN JOURNAL OF INFECTION MICROBES AND ANTIMICROBIALS, 2024, 13
  • [23] Aztreonam plus Clavulanate, Tazobactam, or Avibactam for Treatment of Infections Caused by Metallo-β-Lactamase-Producing Gram-Negative Bacteria
    Emeraud, Cecile
    Escaut, Lelia
    Boucly, Athenais
    Fortineau, Nicolas
    Bonnin, Remy A.
    Naas, Thierry
    Dortet, Laurent
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (05)
  • [24] Synergistic activity of ceftazidime-avibactam and aztreonam against serine and metallo-β-lactamase-producing gram-negative pathogens
    Wenzler, Eric
    Deraedt, Matthew F.
    Harrington, Amanda T.
    Danizger, Larry H.
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2017, 88 (04) : 352 - 354
  • [25] Evaluation of a simple method for testing aztreonam and ceftazidime-avibactam synergy in New Delhi metallo-beta-lactamase producing Enterobacterales
    Khan, Salman
    Das, Arghya
    Vashisth, Deepali
    Mishra, Anwita
    Vidyarthi, Ashima Jain
    Gupta, Raghav
    Begam, Nazneen Nahar
    Kataria, Babita
    Bhatnagar, Sushma
    PLOS ONE, 2024, 19 (05):
  • [26] Aztreonam Combination Therapy: An Answer to Metallo-β-Lactamase-Producing Gram-Negative Bacteria?
    Shields, Ryan K.
    Doi, Yohei
    CLINICAL INFECTIOUS DISEASES, 2020, 71 (04) : 1099 - 1101
  • [27] The paradoxical in vivo activity of β-lactams against metallo-β-lactamase-producing Enterobacterales is not restricted to carbapenems
    Abdelraouf, Kamilia
    Reyes, Sergio
    Nicolau, David P.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2021, 76 (03) : 684 - 691
  • [28] New Delhi Metallo-β-Lactamase-Producing Enterobacterales Bacteria, Switzerland, 2019-2020
    Findlay, Jacqueline
    Poirel, Laurent
    Kessler, Julie
    Kronenberg, Andreas
    Nordmann, Patrice
    EMERGING INFECTIOUS DISEASES, 2021, 27 (10) : 2628 - 2637
  • [29] Therapeutic Options for Metallo-β-Lactamase-Producing Enterobacterales (vol 14, pg 125, 2021)
    Tan, X.
    Kim, H. S.
    Baugh, K.
    INFECTION AND DRUG RESISTANCE, 2021, 14 : 595 - 595
  • [30] In vitro synergistic activity of aztreonam (AZT) plus novel and old β-lactamase inhibitor combinations against metallo-β-lactamase-producing AZT-resistant Enterobacterales
    Cervino, Ivan
    Gonzalez, Deborah
    Nastro, Marcela
    Vega, Juana
    Reyes, Ana Paula
    Buriano, Gisella
    Vay, Carlos
    Famiglietti, Angela
    Hernan Rodriguez, Carlos
    JOURNAL OF MEDICAL MICROBIOLOGY, 2021, 70 (10)